Literature DB >> 21864484

Treatment with beta-hydroxybutyrate and melatonin is associated with improved survival in a porcine model of hemorrhagic shock.

Kristine E Mulier1, Daniel R Lexcen, Elizabeth Luzcek, Joseph J Greenberg, Gregory J Beilman.   

Abstract

INTRODUCTION: The neuroprotective ketone β-hydroxybutyrate (BHB) and the antioxidant melatonin have been found at elevated levels in hibernating mammals. Previous studies in rat models of hemorrhagic shock have suggested a benefit. We compared infusion of 4M BHB and 43 mM melatonin (BHB/M) to 4M sodium chloride and 20% DMSO (control solution) to evaluate for potential benefits in porcine hemorrhagic shock.
METHODS: Hemorrhagic shock was induced to obtain systolic blood pressures <50 mmHg for 60 min. Pigs were treated with a bolus of either BHB/M (n=9) or control solution (n=8) followed by 4-h infusion of the either BHB/M or control solution. All animals were then resuscitated for 20 h after shock. Physiological data were continually recorded, and blood samples were taken at intervals throughout the experiment. Serum samples were analyzed via high resolution NMR for metabolomic response.
RESULTS: BHB/M treatment significantly increased 24-h survival time when compared to treatment with control solution (100% versus 62%; p=0.050), with a trend toward decreased volume of resuscitative fluid administered to animals receiving BHB/M. BHB/M-treated animals had lower base deficit and higher oxygen consumption when compared to animals receiving control solution. Serum metabolite profiles revealed increases in β-hydroxybutyrate (BHB), succinate, 2-oxovalerate and adipate with BHB/M treatment as compared with animals treated with control infusion.
CONCLUSION: Infusion of BHB/M conferred a survival benefit over infusion of control solution in hemorrhagic shock. BHB and its products of metabolism are identified in serum of animals subjected to shock and treated with BHB/M. Further preclinical studies are needed to clarify the mechanisms of action of this promising treatment strategy.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864484     DOI: 10.1016/j.resuscitation.2011.08.003

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  8 in total

1.  Hibernation-based blood loss therapy increases survivability of lethal hemorrhagic shock in rats.

Authors:  Cecilia E Perez de Lara Rodriguez; Lester R Drewes; Matthew T Andrews
Journal:  J Comp Physiol B       Date:  2017-03-21       Impact factor: 2.200

Review 2.  Pathophysiology of Hemorrhage as It Relates to the Warfighter.

Authors:  Carmen Hinojosa-Laborde; Ian L Hudson; Evan Ross; Lusha Xiang; Kathy L Ryan
Journal:  Physiology (Bethesda)       Date:  2022-01-10

Review 3.  Circannual transitions in gene expression: lessons from seasonal adaptations.

Authors:  Christine Schwartz; Matthew T Andrews
Journal:  Curr Top Dev Biol       Date:  2013       Impact factor: 4.897

4.  Assessment of prehospital hemorrhage and airway care using a simulation model.

Authors:  Mariya E Skube; Seth Witthuhn; Kristine Mulier; Bonnie Boucher; Elizabeth Lusczek; Greg J Beilman
Journal:  J Trauma Acute Care Surg       Date:  2018-07       Impact factor: 3.313

Review 5.  Ketone bodies as signaling metabolites.

Authors:  John C Newman; Eric Verdin
Journal:  Trends Endocrinol Metab       Date:  2013-10-18       Impact factor: 12.015

Review 6.  β-hydroxybutyrate: much more than a metabolite.

Authors:  John C Newman; Eric Verdin
Journal:  Diabetes Res Clin Pract       Date:  2014-08-19       Impact factor: 5.602

7.  D-β-Hydroxybutyrate and melatonin for treatment of porcine hemorrhagic shock and injury: a melatonin dose-ranging study.

Authors:  Andrea Wolf; Kristine E Mulier; Sydne L Muratore; Gregory J Beilman
Journal:  BMC Res Notes       Date:  2017-11-29

8.  1H-NMR metabolomic biomarkers of poor outcome after hemorrhagic shock are absent in hibernators.

Authors:  Lori K Bogren; Carl J Murphy; Erin L Johnston; Neeraj Sinha; Natalie J Serkova; Kelly L Drew
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.